Evaluation and Management of Atrial Fibrillation

Purpose

Background/Definitions

Inclusion Criteria

Exclusion Criteria

Diagnostic Evaluation

Practice Recommendations for Management 

Outcome Measures and Guideline Adherence

Key Contributors

Last Updated

February, 2023

References

  1. 2019 AHA/ACC/HRS Update
  2. 2014 AHA/ACC/HRS Guideline
  3. Um K et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21(6):856-863.
  4. Arrigo M et al. Disappointing success of electrical cardioversion for new-onset atrial fibrillation in cardiosurgical ICU patients. Crit Care Med. 2015;43(11):2354-2359.
  5. Walkey AJ et al. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. Chest. 2016;149:74-83.
  6. Bosch NA et al. Comparative effectiveness of heart rate control medications for the treatment of sepsis-associated atrial fibrillation. Chest. 2021;159(4):1452-1459.
  7. Davey MJ et al. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med. 2005;45(4):347-353.
  8. Onalan O et al. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. Am J Cardiol. 2007;99(12):1726-1732.
  9. Bosch NA et al. Atrial fibrillation in the ICU. Chest. 2018;154:1424-1434.

Supplemental Materials


Revision #1
Created 22 May 2023 17:43:06 by Emily Cantrell
Updated 10 October 2023 12:47:15 by Emily Cantrell